Form 4: REGENXBIO Director Kenneth T. Mills Executes Stock Option and Sells Shares

REGENXBIO director Kenneth T. Mills exercised stock options and sold shares of common stock on July 24 and 25, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Kenneth T. Mills, a director at REGENXBIO Inc., executed stock options to purchase shares of common stock on July 24 and 25, 2024.
• On July 24, 2024, Mills exercised options for 12,221 shares at a price of $3.76 per share and sold the same amount of shares at a weighted average price of $13.7823.
• On July 25, 2024, Mills exercised options for 15,369 shares at a price of $3.76 per share and sold the same amount of shares at a weighted average price of $13.9567.
• These transactions were executed under a Rule 10b5-1 trading plan.
• Following these transactions, Mills directly owns 408,035 shares of REGENXBIO common stock and holds options to purchase 51,354 shares.

Sentiment

Score: 5

Explanation: This is a neutral disclosure of stock transactions by a company director. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

This is a routine disclosure of insider trading activity. It is common for executives and directors to have pre-arranged trading plans to avoid accusations of trading on inside information.

Stakeholder Impact

• The sale of shares by a director could have a minor negative impact on shareholder sentiment, but the existence of a 10b5-1 plan mitigates this concern.

Key Dates